KPV Research Brief: An α-MSH Tripeptide in Intestinal Inflammation Models
KPV is the three-amino-acid C-terminal fragment of α-MSH. This brief summarises the cell and mouse colitis studies, including PepT1-mediated uptake and nanoparticle delivery, and what remains untested in people.
LWL Research Brief
Evidence · Early01Preclinical: intestinal cell and mouse colitis models.
- 02Population
- Intestinal epithelial cells; mouse models of colitis and inflammatory bowel disease.
- 03Intervention
- KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH, including nanoparticle-delivered forms.
- 04Primary endpoint
- Intestinal inflammation and pro-inflammatory signalling markers.
05Results
- PepT1-mediated uptake of KPV reduced intestinal inflammation in cell and mouse models (Gastroenterology 2008).
- KPV showed anti-inflammatory potential in murine IBD models (Inflamm Bowel Dis 2008).
06Limitations
- All cited work is preclinical; no controlled human trials are cited.
- Delivery method (oral, nanoparticle) strongly shapes the reported effect.
07What this evidence does NOT demonstrate
- Any effect on gut, skin or inflammatory conditions in people.
- A safe or effective human dose.
08Citations
- Dalmasso et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. PMID 18061177 ↗
- Kannengiesser et al. KPV has anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis, 2008. PMID 18092346 ↗
- Orally targeted delivery of KPV via hyaluronic acid nanoparticles in colitis. Mol Ther, 2017. PMID 28143741 ↗
Summary of published literature · For research use only · Not medical advice
Alpha-MSH is a hormone with a long-recognised anti-inflammatory action. KPV — lysine, proline, valine — is the three-amino-acid tail at its C-terminal end, and researchers found that this fragment retains much of the parent hormone's inflammatory signalling activity without carrying the rest of the molecule with it.
Why the size matters
Alpha-MSH also affects pigmentation, because that is what melanocyte-stimulating hormone does. Isolating the KPV fragment separates the inflammatory signalling from that pigmentation activity. It is a good example of why peptide research so often works with fragments rather than whole proteins: you keep the action you are studying and leave behind the ones you are not.
Its size also means it can enter cells directly, which is the basis of the research into its intracellular action rather than purely receptor-surface effects.
Inflammation is not the enemy
Worth stating plainly, because the marketing around anti-inflammatory compounds usually gets this wrong: inflammation is the repair response. It is how damaged tissue recruits attention. The problem case is not inflammation, it is inflammation that does not resolve and stays switched on after it has done its job.
That distinction is why KPV is studied as a modulator of excessive inflammatory signalling rather than as a blanket suppressant, and why it appears in blends alongside repair peptides rather than in place of them. In the KLOW stack it is the component that keeps the environment stable enough for the other three to work in.
Where the research clusters
- Intestinal inflammation: the largest body of work, following the gut's own inflammatory load.
- Skin: inflammatory skin conditions, both topical and systemic research routes.
- Systemic inflammatory signalling: as a general modulator in combination protocols.
What we supply
Our KPV is a 10 mg lyophilised vial, HPLC-verified, with a purity Certificate of Analysis available on request.
Supplied strictly for laboratory research purposes. Not for human or veterinary use.
Reviewed for research accuracy. Educational / research context only — not medical advice.
